TRVI Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions...

Stats
Dagens volum	26 782.00
Gjennomsnittsvolum	309 826
Markedsverdi	208.26M
EPS	$0 ( 2024-03-20 )
Neste inntjeningsdato	( $-0.0900 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.41
ATR14	$0.0190 (0.63%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-15	Galletta Christopher	Buy	28 500	Stock Option (right to buy)
2024-02-15	Simon Farrell	Buy	175 000	Stock Option (right to buy)
2024-02-15	Clark David J	Buy	175 000	Stock Option (right to buy)
2024-02-15	Good Jennifer L	Buy	630 000	Stock Option (right to buy)
2024-02-15	Sciascia Thomas	Buy	150 000	Stock Option (right to buy)

INSIDER POWER
78.91
Last 98 transactions
Buy: 31 017 280 \| Sell: 1 379 035

Volum Korrelasjon

Lang: 0.11 (neutral)

Kort: 0.84 (strong)

Signal:(50.831) Same movement expected

Trevi Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
HAPP	0.964
ADSE	0.959
CRTO	0.957
TXRH	0.956
EQ	0.952
KRTX	0.951
AIHS	0.949
MEDP	0.949
KBAL	0.948
TA	0.948

10 Mest negative korrelasjoner
CYAN	-0.955
WTER	-0.954
DCRC	-0.954
SSRM	-0.952
BIOL	-0.947
WISA	-0.94
CYXT	-0.939
UTMD	-0.938
IMKTA	-0.928
PYR	-0.926

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Trevi Therapeutics Inc Korrelasjon - Valuta/Råvare

-0.06
( neutral )

-0.51
( weak negative )

0.00
( neutral )

-0.32
( neutral )

-0.26
( neutral )

Trevi Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2023
Omsetning:	$0
Bruttogevinst:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2022
Omsetning:	$0
Bruttogevinst:	$-43 000.00 (0.00 %)
EPS:	$-0.450

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.830

Financial Reports:

No articles found.

Trevi Therapeutics Inc

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Sanntidsoppdatering for Trevi Therapeutics Inc [TRVI]

Upcoming Earnings Alert